Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
2000 Turkeys
Roads, Travel and Traffic
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Jobs
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
2000 Turkeys
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Jobs
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Probe Gold Inc
Edit Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Moderna, Inc. - Common Stock
(NQ:
MRNA
)
254.19
+12.73 (+5.27%)
Delayed Quote
Updated: 4:00 PM EST, Nov 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Moderna, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
S&P 500 Top Movers: Nov. 6, 2026 Gainers and Losers
↗
November 06, 2026
Via
Chartmill
Topics
Stocks
Why is Moderna (MRNA) stock soaring today
November 06, 2026
What happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 6.4% in the afternoon session after the company reported third-quarter 2026 finan...
Via
StockStory
Moderna (MRNA) Q3 2026 Earnings Call Transcript
↗
November 06, 2026
Profitability returned as international partnerships offset a norovirus setback.
Via
The Motley Fool
Topics
Earnings
What Moderna (MRNA) Said on Its Q3 Earnings Call
↗
November 06, 2026
Moderna (NASDAQ:MRNA) raised its 2026 revenue growth outlook after reporting higher third-quarter sales and a return to quarterly profitability, as demand for its COVID-19 vaccines and international...
Via
MarketBeat
Topics
Artificial Intelligence
Earnings
Moderna (NASDAQ:MRNA) Q3 Earnings Beat and Raised Guidance Fuel Stock Rally
↗
November 06, 2026
Via
Chartmill
Topics
Earnings
Moderna Just Gave Investors Yet Another Thing to Cheer About
↗
November 06, 2026
Moderna's cancer vaccine has been the big story this year, but its latest quarter showed the rest of its business is improving, too.
Via
The Motley Fool
Moderna (NASDAQ:MRNA) delivers strong Q3 2026 numbers, stock soars
November 06, 2026
Biotechnology company Moderna (NASDAQ:MRNA) reported Q3 2026 results topping the market’s revenue expectations, with revenue up 29.2% year on year to $1.31 b...
Via
StockStory
S&P 500 After-Hours Movers: ABNB and SNDK Gain, AXON and SOLV Fall
↗
November 05, 2026
Via
Chartmill
Topics
Stocks
Moderna (MRNA) Q3 earnings report preview: what to look for
November 04, 2026
Biotechnology company Moderna (NASDAQ:MRNA) will be reporting earnings this Friday before market hours. Here’s what to expect. Moderna beat analysts’ revenue...
Via
StockStory
Topics
Artificial Intelligence
Universal Health Services, Tenet Healthcare, Moderna, Novavax, and Intuitive Surgical stocks trade up, what you need to know
November 04, 2026
What happened? A number of stocks jumped in the afternoon session after election results confirmed that Democrats reclaimed majorities in the House and Senat...
Via
StockStory
Moderna's Cancer Vaccine Is Incredibly Promising, but This Could Be a Major Obstacle to Its Success
↗
November 03, 2026
Even if the company's vaccine obtains approval, producing it at scale could be a big challenge.
Via
The Motley Fool
Tempus AI Surges on Earnings Beat, But Can the Rally Last?
↗
November 03, 2026
Tempus AI posted Q3 revenue up 23.1% and a surprise profit, raised guidance, and saw shares surge 10%, though analysts cite cash burn and limited 2026 upside.
Via
MarketBeat
Topics
Artificial Intelligence
Earnings
Initial Public Offering
Could Investing in Moderna's Stock Double Your Money?
↗
November 03, 2026
The healthcare stock has generated massive returns this year and may still have room to rise even higher in the future.
Via
The Motley Fool
If Moderna's CEO Is Right, the Stock's Rally Could Just Be Getting Started
↗
November 02, 2026
Stéphane Bancel has high hopes for the company's cancer vaccine, beyond just treating melanoma.
Via
The Motley Fool
Stock Split Watch: Is Moderna Next?
↗
November 02, 2026
Moderna stock has skyrocketed this year.
Via
The Motley Fool
These 2 Stocks Have Skyrocketed in 2026. Here’s Why I’d Stay Away
↗
October 29, 2026
These biotechs’ valuations are through the roof.
Via
The Motley Fool
Will Moderna Soar on Nov. 6?
↗
October 29, 2026
Moderna shares have outperformed tech giants this year.
Via
The Motley Fool
Topics
Artificial Intelligence
Axsome Therapeutics vs. Moderna: Consistent Revenue Growth or Sharp Volatility
↗
October 28, 2026
Axsome's steady ascent has flipped the script—it now outpaces Moderna in quarterly revenue despite starting from a fraction of its size.
Via
The Motley Fool
Merck and Moderna's Cancer Vaccine Worked—Who Gets Paid?
↗
October 27, 2026
Merck and Moderna's melanoma vaccine cut recurrence risk 42% in a Phase 3 trial, but results fell short of hopes, sending Moderna shares down sharply while Merck stock barely moved.
Via
MarketBeat
S&P 500 Premarket Movers: Royal Caribbean, S&P Global Gain; Xylem, Sherwin-Williams Fall
↗
October 27, 2026
Via
Chartmill
Topics
Stocks
S&P 500 Gap-Down Stocks for Oct. 26, 2026
↗
October 26, 2026
Via
Chartmill
Topics
Stocks
S&P 500 Premarket Movers: Gainers and Losers Before the Open
↗
October 26, 2026
Via
Chartmill
Topics
Stocks
Moderna Melanoma Therapy Cuts Recurrence Risk 42% in Phase 3 Trial
↗
October 24, 2026
Moderna (NASDAQ:MRNA) presented Phase 3 results for intismeran, its individualized neoantigen therapy, in combination with Merck’s pembrolizumab for patients with resected high-risk melanoma. The...
Via
MarketBeat
Topics
Artificial Intelligence
Most Active S&P 500 Stocks for Oct. 23, 2026
↗
October 23, 2026
Via
Chartmill
Topics
Stocks
Moderna’s Stock Just Stumbled. Is It a Buy on the Dip?
↗
October 23, 2026
The stock fell 17% in one trading session.
Via
The Motley Fool
S&P 500 Premarket Movers: CCI and SBAC Lead Gainers, TYL and DECK Top Decliners
↗
October 23, 2026
Via
Chartmill
Topics
Stocks
Stock Market Today, Oct. 22: Moderna Stock Plummets 18% on Melanoma Vaccine Data Leak Reports
↗
October 22, 2026
Personalized cancer vaccine material allegedly circulated online ahead of formal Phase 3 results, today, Oct. 22, 2026.
Via
The Motley Fool
Topics
Stocks
Why Moderna (MRNA) stock is trading lower today
October 22, 2026
What happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 22.7% in the afternoon session after the company's partial Phase 3 data for its per...
Via
StockStory
Topics
Government
S&P 500 Top Movers: Gainers and Losers for Oct. 22, 2026
↗
October 22, 2026
Via
Chartmill
Topics
Stocks
Most Active S&P 500 Stocks on Oct. 22: Netflix, Super Micro, Moderna
↗
October 22, 2026
Via
Chartmill
Topics
Stocks
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at
/week.
Subscribe Today